JD Health International Inc. disclosed on 18 May 2026 that it bought back 1.91 million ordinary shares on the Hong Kong Stock Exchange. The repurchase was executed at prices ranging from HKD 42.46 to HKD 43.36 per share, translating to a volume-weighted average cost of HKD 42.89 and an aggregate consideration of HKD 81.85 million.

All shares acquired on 18 May, together with 198,050 shares repurchased on 15 May, are earmarked for cancellation. In total, 2.11 million shares are awaiting cancellation, equivalent to 0.066% of JD Health’s issued share capital of 3.21 billion shares.

The purchases were made under the general mandate approved on 20 June 2025, which authorises JD Health to repurchase up to 320.01 million shares. Following the latest transaction, the company has utilised approximately 0.66% of the mandate’s share limit. A 30-day moratorium on new share issues or treasury-share sales remains in force until 17 June 2026, as required under Hong Kong listing rules.

Apart from the repurchases, JD Health reported no other changes to its issued share capital and holds no treasury shares.